Analysts/Institutional Investor Meet/Con. Call Updates

Date: 19-06-2026 To To The General Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Mumbai - 400 051 Ref: BSE Scrip Code: 533259; NSE Symbol: HEALTHX Dear Sir/Madam, Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Transcript of Group Conference call for Q4 FY26 Ref: Our letter dated 02.06.2026 for intimation of schedule of the Group Conference Call for Q4 FY’26. This is in furtherance to our letter dated June 2, 2026 intimating that a Group Conference Call with investors and analysts was scheduled to be held on 12th June, 2026 at 4.00 PM (IST) to discuss the performance for the quarter and year ended March 31, 2026 and updates of the Company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the transcript of the said call with the Investors and analysts. Please also find herein below the link of the transcript of the said call that has been uploaded on the website of the Company. http://healthxplatform.com/Pdf/HXPL_Q4_FY26_Earnings_Group_Conference_Call_Transcript.pdf You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Health X Platform Limited (formerly known as Sastasundar Ventures Limited) Pratap Singh Company Secretary & Compliance Officer M. No.: ACS-24081 Health X Platform Limited June 2026 Q4 & FY26 Earnings Call - Health X Platform Ltd (earlier Sastasundar Ventures Ltd) Shrutee Barve Hi everyone and a very good afternoon. I welcome you all to Health X Platform Limited Q4 & FY26 Earnings Cum Business Update Call. Please note that the discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks pertaining to the business. We have on call today Mr. Banwari Lal Mittal, the Managing Director and CEO and Mr. Lokesh Agarwal, CFO. So, I now request, I would like to hand over this call to Mittal sir to proceed with the opening remarks. Post that, we'll open the floor for Q&A. Thank you, and over to you, sir. BL Mittal Welcome everyone to Health X Platform Limited (formerly known as SastaSundar Ventures Limited), Q4 and FY26 earning concall. We sincerely appreciate your continued trust and support as we continue building one of India's most capital efficient healthcare platform, focusing on making healthcare affordable, accessible and technology driven. We are delighted to share it here that this year we successfully transitioned to the HealthX identity reflecting our evolution from a healthcare commerce business into a broader healthcare ecosystem, spanning pharmacy distribution, digital healthcare, technology, diagnostic, and preventive care. At HealthX, we are guided by four enduring principles. They shape everything we do. Innovation powered by technology, Value delivered with efficiency, impact driven by empathy, and trust built on authenticity. Our core values being genuine and being child are just not words on a wall. They are the cultural DNA of the organization. We ensure that every product and service we offer is 100% genuine. And like a child, we remain curious, non- discriminatory, emotionally connected, and committed to growing every single day. Before diving into performance, we share a short brief on the company for the new participants today here. Many of you must be knowing we serve India through two powerful and complementary vertical as part of single business ecosystem. Sastasundar App or B2C platform connects consumers directly to genuine medicine, diagnostic and wellness products. We offer real savings, counselling by trained health professionals, and AI-driven personalized care. Retailer Shakti, our B2B platform, is designed to empower India's retail pharmacies. We give them better margins, complete stock availability, transparent pricing, and dedicated support, enabling them to serve their customers with greater efficiency and trust. Together, this platform forms one integrated ecosystem unified by data, AI, and unrelenting commitment to authenticity. Technology remains central to our strategy. We operate through centralized technology enabled fulfilment infrastructure with over 2 lakh square feet of warehousing capacity, more than double our earlier footprint. AI-lead automation across procurement, warehousing, inventory management, and order fulfilment is helping us improve efficiency, accelerate delivery timeline, and create a scalable operating model capable of supporting significantly larger volumes. Coming specifically to FY26, which was indeed an important year for the Company, a major strategic milestone during the year was the launch of JITO, or All Certified Genetic Medicine category. To help the end of extensive pharmacy network, JITO aims to make high-quality health care significantly more affordable by offering medicine at prices up to 60% lower than leading branded alternatives. We believe this initiative has the potential to become an important core driver while further strengthening our mission of affordable health care. On the segment front, our B2B platform, Retailer Shakti, continues to emerge as one of the fastest- growing pharmacy supply chain platforms in India. Since financing in 2019, the business has compounded at nearly 78% CAGR and now sells over 62,000 retail pharmacies, while partnering with more than 700 pharmaceutical companies. Our scale, technology, infrastructure, and deep retailer relationship provide a strong foundation for sustainable long-term growth. On the customer side, for B2B platform, B2C platform, SastaSundar continues to demonstrate strong traction with Health X Platform Limited June 2026 improving customer engagement, repeat purchase, and operating efficiencies. For B2C, business remains highly capital efficient, supported by an inventory-light operating model and a working capital cycle of only 18 days, among the best in the industry. Looking ahead, our focus remain on these strategic priorities, accelerating the growth of retailer safety, scaling up consumer healthcare platform, and expanding the JITO ecosystem across product and healthcare services, while continuing our investment in technology, automation, and platform capabilities that we believe will drive operating leverage and profitability over the coming years. From uniqueness perspective, I would request you to pay your attention on the fact that we measure our capital efficiency by providing the cost of capital at the rate of 9% and this scale of the business is built upon by total capital deployed, including the cost of capital, only rupees 259 crore. Our growth rate, total capital efficiency, consumer experience, technology state and governance is what we are proud of. We remain confident on our long-term vision and continue to target 6,000 crores of revenue by Financial Year 2030, comprising 4,000 crores from B2B Retailer Shakti and 2,000 crores from B2C Operations by Sasta Sundar App, while progressively improving EBITDA margin and maintaining industry-leading working capital efficiency. As you are aware, our board of directors have approved a scheme of simplification of corporate structure. The details have been given in a detailed presentation filed with Stock Exchange under the scheme. The Finance Division shall be demerged and listed separately in the name of Microsec Resources Ltd. The existing shareholders will be allotted one equity share of the Finance Division against 3 equity shares held in the HealthX platform. There will not be any change in the existing shareholding of Health X Platform Ltd. In the hands of existing shareholder, the public shareholder of subsidiary Company, SastaSundar HealthBuddy Limited, shall be allotted shares of Health X Platform Limited [Showing first 8,000 characters — download PDF for full document]